Refocusing Neutralizing Antibody Response by Targeted Dampening of an Immunodominant Epitope

Journal of Immunology

Volumn 159, Issue 1, 1997, Pages 279-289

  Garrity, Robert R ^a,c   Rimmelzwaan, Guus ^b   Minassian, Anton ^a   Tsai, Wen Po ^a   Lin, George ^a,c   De Jong, Jean Jacques ^b   Goudsmit, Jaap ^b   Nara, Peter L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c BMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ANTIBODY;

AMINO ACID SEQUENCE; ARTICLE; CELL LINE; GENETIC TRANSFECTION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MOLECULAR GENETICS; SITE DIRECTED MUTAGENESIS;

AIDS VACCINES; AMINO ACID SEQUENCE; ANTIBODIES, VIRAL; CELL LINE; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNODOMINANT EPITOPES; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; TRANSFECTION;

EID: 0031180974     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Hall, B. F., and K. A. Joiner. 1991. Strategies of obligate intracellular parasites for evading host defenses. Immunol. Today 12:A22.
2. Marrack, P., and J. Kappler. 1994. Subversion of the immune system by pathogens. Cell 76:323.
3. Fitzgerald, D. J., E. D. Bronson, and J. N. Anderson. 1996. Compositional similarities between the human immunodeficiency virus and surface antigens of pathogens. AIDS Res. Hum. Retroviruses 12:99.
4. Coffin, J. M. 1986. Genetic variation in AIDS viruses. Cell 46:1.
5. Haigwood, N. L., J. R. Shuster, G. K. Moore, H. Lee, P. V. Skiles, K. W. Higgins, P. J. Barr, C. George-Nascimento, and K. S. Steimer. 1990. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res. Hum. Retroviruses 6:855.
6. Nara, P. L., R. R. Garrity, and J. Goudsmit, 1991. Neutralization of HIV-1: a paradox of humoral proportions. FASEB J. 5:2437.
7. Garrity, R. R., G. Rimmelzwaan, A. Minassian, W-P. Tsai, G. Lin, S. Conley, N. Dunlop, J. de Jong, W. Keulen, J. Moore, J. Goudsmit, and P. Nara. 1994. Site-directed mutations introduced into the V3 domain of HIV-1 gp120 result in an augmented humoral response to other epitopes. In Vaccines 94. E. Norrby, F. Brown, R. M. Chanock, and H. S. Ginsberg, eds. CSH Press, Cold Spring Harbor, NY. pp. 261-267.
8. Palker, T. J., M. E. Clark, A. J. Langlois, T. J. Matthews, K. J. Weinhold, R. R. Randall, D. P. Bolognesi, and B. F. Haynes. 1988. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc. Natl. Acad. Sci. USA 85:1932.
9. Goudsmit, J., C. Debouck, R. H. Meloen, L. Smit, M. Bakker, D. M. Asher, A. V. Wolff, C. J. Gibbs, Jr., and D. C. Gajdusek. 1988. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc. Natl. Acad. Sci. USA 85: 4478.
10. Nara, P. L., L. Smit, N. Dunlop, W. Hatch, M. Merges, D. Waters, J. Kelliher, R. C. Gallo, P. J. Fischinger, and J. Goudsmit. 1990. Emergence of viruses resistant to neutralizution by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J. Virol. 64:3779.
11. di Marzo Veronese, F., M. S. Reitz, Jr., G. Gupta, M. Robert-Guroff, C. Boyer-Thompson, A. Louie, R. C. Gallo, and P. Lusso. 1993. Loss of a neutralizing epitope by a spontaneous point mutation in the V3 loop of HIV-1 isolated from an infected laboratory worker. J. Biol. Chem. 268:25894.
12. McKnight, A., R. A. Weiss, C. Shotton, Y. Takeuchi, H. Hoshino, and P. R. Claphum, 1995 Change in tropism upon immune escape by human immunodeficiency virus. J. Virol. 69:3167.
13. Walker M. C., and P. E. Fast. 1994. Clinical trials of candidate AIDS vaccines. AIDS 8(Suppl. 1):S213.
14. Graham, B. S., and P. F. Wright. 1995. Candidate AIDS vaccines. N. Engl. J. Med. 333:1331.
15. Girard, M., B. Meignier, F. Barre-Sinoussi, M. P. Kieny, T. Matthews, E. Muchmore, P. L. Nara, Q. Wei, L. Rimsky, K. Weinhold, and P. Fultz. 1995. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J. Virol. 69:6239.
16. Berman, P. W., K. K. Murthy, T. Wrin, J. C. Vennari, E. K. Cobb, D. J. Eastman, M. Champe, G. R. Nakamura, D. Davison, M. F. Powell, J. Bussiere, D. P. Francis, T. Matthews, T. J. Gregory, and J. F. Obijeski. 1996. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J. Infect. Dis. 173:52.
17. Modrow, S., B. H. Hahn, G. M. Shaw, R. C. Gallo, F. Wong-Staal, and H. Wolf. 1987. Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions. J. Virol. 61:570.
18. Lauder, I. J., J. L. Hsiang, J. Lin, E. B. Siwak, and F. B. Hollinger. 1996. Kernel density analysis of variable and conserved regions of the envelope proteins of human immunodeficiency virus type 1 and associated epilopes. AIDS Res. Hum. Retroviruses 12:91.
19. Fung, M. S., C. R. Sun, W. L. Gordon, R. S. Liou, T. W. Chang, W. N. Sun, E. S. Daar, and D. D. Ho. 1992. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J. Virol. 66:848.
20. Sullivan, N., M. Thali, C. Furman, D. D. Ho, and J. Sodroski. 1993. Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. J. Virol. 67:3674.
21. Nakamura, G. R., R. Byrn, D. M. Wilkes, J. A. Fox, M. R. Hobbs, R. Hastings, H. C. Wessling, M. A. Norcross, B. M. Fendly, and P. W. Berman. 1993. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1. J. Virol. 67:6179.
22. Emini, E. A., P. L. Nara, W. A. Schleif, J. A. Lewis, J. P. Davide, D. R. Lee, J. Kessler, S. Conley, S. Matsushita, S. D. Putney, R. Garrity, and J. W. Eichberg. 1990. Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J. Virol. 64:3674.
23. Wang, C. Y., D. J. Looney, M. L. Li, A. M. Walfield, J. Ye, B. Hosein, J. P. Tam, and F. Wong-Staal. 1991. Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science 256:1687.
24. Ahlers, J. D., C. D. Pendleton, N. Dunlop, A. Minassian, P. L. Nara. and J. A. Berzofsky. 1993. Construction of an HIV-1 peptide vaccine containing a multi-determinant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations. J. Immunol. 150:5647.
25. Spear, G. T., D. M. Takefman, S. Sharpe, M. Ghassemi, and S. Zolla-Pazner. 1994. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization. Virology 204:609.
26. Zwart, G., N. K. Back, C. Ramautarsing, M. Valk, L. van der Hoek, and J. Goudsmit. 1994. Frequent and early HIV-1 MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain. AIDS Res. Hum. Retroviruses 10:245.
27. Kohler, H., J. Goudsmit, and P. Nara. 1992. Clonal dominance: cause for a limited and failing immune response to HIV-1 infection and vaccination. J. Acquired Immune Defic. Syndr. 5:158.
28. Muller, S., H. Wang, G. J. Silverman, G. Bramlet, N. Haigwood, and H. Kohler. 1993. B-cell abnormalities in AIDS: stable and clonally restricted antibody response in HIV-1 infection. Scand. J. Immunol. 38:327.
29. Metlas, R., and V. Veljkovic. 1995. Does the HIV-1 manipulate immune network via gp120 immunoglobulin-like domain involving V3 loop? Vaccine 13:355.
30. Ho, D. D., J. A. McKeating, X. L. Li, T. Moudgil, H. S. Daar, NC. Sun, and J. E. Robinson. 1991. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J. Virol. 65:489.
31. Kang, C. Y., P. Nara, S. Chamat, V. Caralli, T. Ryskamp, N. Haigwood, R. Newman, and H. Kohler. 1991. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans. Proc. Natl. Acad. Sci. USA 88:6171.
32. Berkower, I., G. E. Smith, C. Giri, and D. Murphy, 1989. Human immunodeficiency virus 1: predominance of a group-specific neutralizing epitope that persists despite genetic variation. J. Exp. Med. 170:681.
33. Profy, A. T., P. A. Salinas, L. I. Eckler, N. M. Dunlop, P. L. Nuru, and S. D. Putney. 1990. Epitopes recognized by the neutralizing antibodies of un HIV-1-infected individual. J. Immunol. 144:4641.
34. Moore, J. P., and D. D. Ho. 1993. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J. Virol. 67:863.
35. Robinson, J. E., D. Holton, S. Pacheco-Morell, J. Liu, and H. McMurdo. 1990. Identification of conserved and variant epitopes of human immunodeficiency virus type 1 (HIV-1) gp120 by human monoclonal antibodies produced by EBV-transformed cell lines. AIDS Res. Hum. Retroviruses 6:567.
36. Posner, M. R., T. Hideshima, T. Cannon, M. Mukherjee, K. H. Mayer, and R. A. Byrn. 1991. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. J. Immunol. 146:4325.
37. Bagley, J., P. J. Dillon, C. Rosen, J. Robinson, J. Sodroski, and W. A. Marasco. 1994. Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120. Mol. Immunol. 31:1149.
38. Nara, P. L., W. G. Robey, L. O. Arthur, D. M. Asher, A. V. Wolff, C. J. Gibbs, Jr., D. C. Gajdusek, and P. J. Fischinger. 1987. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses. J. Virol. 61:3173.
39. Goudsmit, J., C. Thiriart, L. Smit, C. Bruck, and C. J. Gibbs. 1988. Temporal development of cross-neutralization between HTLV-III B and HTLV-HI RF in experimentally infected chimpanzees. Vaccine 6:229.
40. Bolognesi, D. P. 1989. Prospects for prevention of and early intervention against HIV. J. Am. Med. Assoc. 261:3007.
41. Burton, D. R., J. Pyati, R. Koduri, S. J. Sharp, G. B. Thornton, P. W. Parren, L. S. Sawyer, R. M. Hendry, N. Dunlop, P. L. Nara, M. Lamacchia, E. Garratty, E. Stiehm, Y. Bryson, Y. Cao, J. Moore, O. Ho, and C. Barbas III. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024.
42. de Jong, J. J., J. Goudsmit, W. Keulen, B. Klaver, W. Krone, M. Tersmette, and A. de Ronde. 1992. Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J. Virol. 66:757.
43. Earl, P., and B. Moss. 1990. Expression of proteins in mammalian cells using vaccinia. In Current Protocols in Molecular Biology, Vol 2, F. M. Ausubet, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl, eds. Greene Publishing Associates and Wiley-Interscience, New York, pp. 16.15.1-16.18.9.
44. Hammar, L., S. Eriksson, and B. Morein. 1989. Human immunodeficiency virus glycoproteins: lectin binding properties. AIDS Res. Hum. Retroviruses 5:495.
45. Skinner, M. A., R. Ting, A. J. Langlois, K. J. Weinhold, H. K. Lyerly, K. Javaherian, and T. J. Matthews. 1988. Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. AIDS Res. Hum. Retroviruses 4:187.
46. Matsushita, S., M. Robert-Guroff, J. Rusche, A. Koito, T. Hattori, H. Hoshino, K. Javaherian, K. Takatsuki, and S. Putney. 1988. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J. Virol. 62:2107.
47. Nara, P. L., and P. J. Fischinger. 1988. Quantitative infectivity assay for HIV-1 and-2. Nature 332:469.
48. Kornfeld, R., and S. Kornfeld. 1985. Assembly of asparagine-linked oligosaccharides. Annu. Rev. Biochem. 54:631.
49. Ratner, L., A. Fisher, L. L. Jagodzinski, H. Mitsuya, R. S. Liou, R. C. Gallo, and F. Wong-Staal. 1987. Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res. Hum. Retroviruses 3:57.
50. Higuchi, R., B. Krummel, and R. K. Saiki. 1988. A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. Nucleic Acids Res, 16:7351.
51. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Ruker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1, J. Virol. 67:6642.
52. Matthews, T. J., K. J. Weinhold, H. K. Lyerly, A. J. Langlois, H. Wigzell, and D. P. Bolognesi. 1987. Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. Proc. Natl. Acad. Sci. USA 84:5424.
53. Leonard, C. K., M. W. Spellman, L. Riddle, R. J. Harris, J. N. Thomas, and T. J. Gregory. 1990. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type I recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265:10,373.
54. LaRosa, G. J., J. P. Davide, K. Weinhold, J. A. Waterbury, A. T. Profy, J. A. Lewis, A. J. Langlois, G. R. Dreesman, R. N. Boswell, P. Shadduck, L. H. Holley, M. Karpus, D. P. Bolognesi, T. J. Matthews, E. Emini, and S. Putney. 1990. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. [Published erratum appears in 1991 Science 251:811.] Science 249:932.
55. Bause, E. 1983. Structural requirements of N-glycosylation of proteins: studies with proline peptides as conformational probes. Biochem. J. 209:33.
56. Chandrasekhar, K., A. T. Profy, and H. J. Dyson. 1991. Solution conformational preferences of immunogenic peptides derived from the principal neutralizing determinant of the HIV-1 envelope glycoprotein gp120. Biochemistry 30:9187.
57. Cease, K. B. 1990. Peptide component vaccine engineering: targeting the AIDS virus. Int. Rev. Immunol. 7:85.
58. Ivanoff, L. A., J. W. Dubay, J. F. Morris, S. J. Roberts, L. Gutshall, E. J. Sternberg, E. Hunter, T. J. Matthews, and S. R. Petteway, Jr, 1902. V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity. Virology 187:423.
59. Stamatatos, L., and C. Cheng-Mayer. 1993. Evidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-forming ability. J. Virol. 67:5635.
60. Lopalco, L., C. De Santis, R. Meneveri, R. Longhi, E. Ginelli, F. Grassi, A. G. Siccardi, and A. Beretta, 1993. Human immunodeficiency virus type 1 gp120 C5 region mimics the HLA class I alpha 1 peptide-binding domain. Eur. J. Immunol. 23:2016.
61. Chen, Y. H., A. Susanna, G. Bock, F. Steindl, H. Katinger, and M. P. Dierich. 1994. HIV-1 gp41 shares a common immunologic determinant with human T, B and monocyte cell lines. Immunol. Lett. 39:219.
62. Back, N. K., L. Smit, J. J. De Jong, W. Keulen, M. Schutten, J. Goudsmit, and M. Tersmette. 1994. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 199:431.
63. Wyatt, R., N. Sullivan, M. Thali, H. Repke, D. Ho, J. Robinson, M. Posner, and J. Sodroski. 1993. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J. Virol. 67:4557.
64. Olshevsky, U., E. Helseth, C. Furman, J. Li, W. Haseltine, and J. Sodroski. 1990. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J. Virol. 64:5701.
65. Thali, M., C. Furman, D. D. Ho, J. Robinson, S. Tilley, A. Pinter, and J. Sodroski. 1992. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glyco-protein. J. Virol. 66:5635.
66. van Tijn, D. A., C. A. Boucher, M. Bakker, and J. Goudsmit. 1989. Antigenicity of linear B-cell epitopes in the C1, V1, and V3 region of HIV-1 gp120. J. Acquired Immune Defic. Syndr. 2:303.
67. Pincus, S. H., K. G. Messer, P. L. Nara, W. A. Blattner, G. Colclough, and M. Reitz. 1994. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers. J. Clin. Invest. 93:2505.
68. Gorny, M. K., J. Y. Xu, S. Karwowska, A. Buchbinder, and S. Zolla-Pazner. 1993. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 150:635.
69. Neurath, A. R., N. Strick, and E. S. Lee. 1990. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides. J. Gen. Virol. 71:85.
70. Niedrig, M., H. P. Harthus, J. Hinkula, M. Broker, H. Bickhard, G. Pauli, H. R. Gelderblom, and B. Wahren. 1992. Inhibition of viral replication by monoclonal antibodies directed against human immunodeficiency virus gp120. J. Gen. Virol. 73:2451.
71. Vijayakrishnan, L., V. Kumar, J. N. Agrewala, G. C. Mishra, and K. V. Rao. 1994. Antigen-specific early primary humoral responses modulate immunodominance of B cell epitopes. J. Immunol. 153:1613.
72. Agarwal, A., S. Sarkar, C. Nazabal, G. Balasundaram, and K. V. Rao. 1996. B cell responses to a peptide epitope. J. Immunol. 157:2779.
73. Cease, K. B., W. S. Probert, L. M. Groenveld, N. M. Dunlop, and P. L. Nara. 1992. Mapping neutralizing epitopes near the fusion segment of HIV gp41. In Vaccines 92. F. Brown, R. M. Chanock, H. S. Ginsberg, and R. A. Lerner, eds. CSH Press, Cold Spring Harbor, NY. pp. 201-204.
74. Lane, H. C., H. Masur, L. C. Edgar, G. Whalen, A. H. Rook, and A. S. Fauci. 1983. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 309:453.
75. Martinez-Maza, O., E. Crabb, R. T. Mitsuyasu, J. L. Fahey, and J. V. Giorgi. 1987. Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity. J. Immunol. 138:138.
76. Kohler, H., Müller, S. and P. L. Nara. 1994. Deceptive imprinting in the immune response against HIV-1. Immunol. Today 15:475.